您的位置：首页 > 产品中心 > 1435467-38-1， PF-06281355
PF-06281355
产品别名
1435467-38-1
PF-06281355
PF-1355
6-(2,5-Dimethoxyphenyl)-3,4-dihydro-4-oxo-2-thioxo-1(2H)-pyrimidineacetamide
PF 6281355
基本信息
| Empirical Formula【经验(实验)分子式】 | C14H15N3O4S |
| Molecular weight | 321.35 |
| NACRES | NA.77 |
| Biochem/physiol Actions【生化/生理作用】 | PF-06281355 (PF-1355) is an orally available, selective and potent mechanism based inhibitor of the myeloperoxidase (MPO) that reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. PF-06281355 suppresses albuminuria and chronic renal dysfunction in model of anti-Glomerular Basement Membrane (GBM) disease. |
| Other Notes【其他说明】 | This compound was developed by Pfizer for Nitric Oxide & Cell Stress research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer. |
| Legal Information【法律信息】 | Sold for research purposes under agreement from Pfizer Inc. Pfizer is a registered trademark of Pfizer, Inc. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| manufacturer/tradename | Pfizer® |
| color【颜色】 | white to beige |
| solubility【溶解性】 | DMSO: 10 mg/mL, clear (warmed) |
| originator【创始人】 | Pfizer |
| storage temp.【储存温度】 | room temp |
| packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
| Pictograms【象形图】 | GHS07 |
| Signal word【警示用语：】 | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral |
| Storage Class Code【储存分类代码】 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
